Palvella Therapeutics, Inc. (PVLA) Net Margin (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Net Margin for 11 consecutive years, with 14827.66% as the latest value for Q3 2024.
- On a quarterly basis, Net Margin rose 1511260.0% to 14827.66% in Q3 2024 year-over-year; TTM through Dec 2024 was 290566.67%, a 29065481.0% decrease, with the full-year FY2024 number at 4054.42%, up 361736.0% from a year prior.
- Net Margin was 14827.66% for Q3 2024 at Palvella Therapeutics, up from 72766.67% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 14827.66% in Q3 2024 to a low of 72766.67% in Q2 2024.
- A 5-year average of 3528.66% and a median of 181.83% in 2022 define the central range for Net Margin.
- Biggest YoY gain for Net Margin was 1511260bps in 2024; the steepest drop was -7277933bps in 2024.
- Palvella Therapeutics' Net Margin stood at 817.06% in 2020, then surged by 88bps to 99.36% in 2021, then tumbled by -83bps to 181.83% in 2022, then skyrocketed by 80bps to 37.0% in 2023, then surged by 40179bps to 14827.66% in 2024.
- Per Business Quant, the three most recent readings for PVLA's Net Margin are 14827.66% (Q3 2024), 72766.67% (Q2 2024), and 5808.51% (Q1 2024).